Mandate

Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals

January 24, 2011

Vinge has advised Industrifonden in connection with its SEK 40 million investment in InDex Pharmaceuticals. InDex Pharmaceuticals develops Kappaproct, a drug developed for the treatment of severe inflammatory bowel disease. Further capital has also been raised from current shareholders, including SEB Venture Capital, which has invested an additional SEK 35 million. The financing will predominantly be used to conduct a clinical phase III trial using Kappaproct with the aim of obtaining market approval.

Vinge’s team consisted of, among others, project manager Johan Larsson and Petter Kjöllerström, who was responsible for the due diligence phase of the transaction. Johan Winnerblad was the responsible partner.

New partners and counsels appointed at Vinge’s Stockholm office

Advokat Sofie Bjärtun, advokat Rikard Lindahl, advokat Malin Malm Waerme and advokat Daniel Wendelsson at Vinge’s Stockholm office have been appointed as new partners as of 1 January 2022. The following lawyers have been elected as counsels at Vinge’s Stockholm office: Advokat Stojan Arnerstål, advokat Amanda Knutsson, advokat Jolene Reimerson, advokat Linnéa Sellström and advokat Filip Öhrner.
July 06, 2021

EU climate taxonomy – New regulations concerning companies’ publication of information

According to the European Union’s climate taxonomy, certain organisations must publish to what extent their operations are environmentally sustainable. In order to clarify what information the companies need to report, as well as how this should be done, the EU Commission has prepared a new delegated regulation. Primarily, the delegated regulation establishes relevant financial key ratios and different report precedents.
June 21, 2021

What an employer should know about the New Whistleblowing Act

Why adopt a new Whistleblowing Act when the current act was adopted as late as 2017?
June 15, 2021